Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873301 | 0.90 | DRD2 (0.36) | SMN1; SMN2KDM4ELMNADRD4DRD2 | |
| SCHEMBL20873249 | 0.90 | DRD4 (0.39) | LMNADRD4DRD2MAPTHTR7 | |
| SCHEMBL20873282 | 0.89 | MEN1 (0.43) | SMN1; SMN2KDM4EDRD4DRD2MEN1 | |
| SCHEMBL21112944 | 0.85 | ALDH1A1 (0.42) | KDM4EDRD4DRD2HTR7ALDH1A1 | |
| SCHEMBL20873256 | 0.82 | KDM4E (0.46) | SMN1; SMN2KDM4EDRD4DRD2MEN1 | |
| SCHEMBL24137896 | 0.80 | LMNA (0.46) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL21112900 | 0.79 | MAPT (0.51) | SMN1; SMN2KDM4ELMNAMAPTHTR7 | |
| SCHEMBL20873320 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL21112915 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL24145059 | 0.69 | HTR7 (0.37) | SMN1; SMN2KDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| EP-3463480-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | SMN1; SMN2 4049/4885KDM4E 4398/4885LMNA 4544/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | SMN1; SMN2 4049/4885KDM4E 4398/4885LMNA 4544/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | SMN1; SMN2 4049/4885KDM4E 4398/4885LMNA 4544/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | SMN1; SMN2 4049/4885KDM4E 4398/4885LMNA 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.